Literature DB >> 1701480

Structure and composition of a family of human cytomegalovirus glycoprotein complexes designated gC-I (gB).

B Kari1, Y N Liu, R Goertz, N Lussenhop, M F Stinski, R Gehrz.   

Abstract

Murine monoclonal antibodies (MAbs) were made to the 52,000 (gp52) and the 93,000 to 130,000 Mr (gp93-130) glycoproteins from a human cytomegalovirus (HCMV) glycoprotein complex designated gC-I or the gB homologue. MAbs recognizing either gp52 or gp93-130 could immunoprecipitate unreduced gC-I complexes from non-ionic detergent extracts of HCMV. Western blotting was performed with immunoaffinity-purified gC-I complexes which were reduced prior to analysis. MAbs made against gp52 recognized gp52 and a 158,000 Mr glycoprotein (gp158). MAbs which recognized gp93-130 in a Western blot also reacted with gp158, which is a gC-I precursor glycoprotein. The origin of gp93-130 was demonstrated by the reactivity of our gp93-130 MAbs with a recombinant protein containing the N-terminal portion of the gB gene. These data are consistent with the hypothesis that gp52 and gp93-130 are generated from the same high Mr precursor by proteolysis. MAbs recognizing either gp52 or gp93-130 neutralized Towne strain HCMV, but MAbs recognizing gp52 required complement to neutralize whereas MAbs recognizing gp93-130 did not. It was also determined that gp93-130 and gp 158 have detectable amounts of O-linked glycans but gp52 does not, showing a difference in the glycosylation of these glycoproteins. Analysis of gC-I disulphide bonds showed that two types were present, one which was very susceptible to reduction and a second which was less susceptible. These complexes could consist of very susceptible inter-complex disulphide bonds and less susceptible intra-complex disulphide bonds.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1701480     DOI: 10.1099/0022-1317-71-11-2673

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  11 in total

1.  A continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus.

Authors:  B Wagner; B Kropff; H Kalbacher; W Britt; V A Sundqvist; L Ostberg; M Mach
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

2.  Oligomerization of the human cytomegalovirus major envelope glycoprotein complex gB (gp55-116).

Authors:  W J Britt; L G Vugler
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

3.  Recombinant cytomegalovirus glycoprotein B vaccine: Rethinking the immunological basis of protection.

Authors:  Mark R Schleiss
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-06       Impact factor: 11.205

4.  Characterization of a panel of insertion mutants in human cytomegalovirus glycoprotein B.

Authors:  J Singh; T Compton
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

5.  The N-terminal 513 amino acids of the envelope glycoprotein gB of human cytomegalovirus stimulates both B- and T-cell immune responses in humans.

Authors:  Y N Liu; A Klaus; B Kari; M F Stinski; J Eckhardt; R C Gehrz
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

6.  Coiled-coil domains in glycoproteins B and H are involved in human cytomegalovirus membrane fusion.

Authors:  Matthew Lopper; Teresa Compton
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

7.  The dominant linear neutralizing antibody-binding site of glycoprotein gp86 of human cytomegalovirus is strain specific.

Authors:  M Urban; W Britt; M Mach
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

8.  An immortalized human fibroblast cell line is permissive for human cytomegalovirus infection.

Authors:  T Compton
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

9.  A human cytomegalovirus glycoprotein complex designated gC-II is a major heparin-binding component of the envelope.

Authors:  B Kari; R Gehrz
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

10.  Identification of the murine cytomegalovirus glycoprotein B gene and its expression by recombinant vaccinia virus.

Authors:  M Rapp; M Messerle; B Bühler; M Tannheimer; G M Keil; U H Koszinowski
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.